- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 22.03. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Eterna Therapeutics Inc. - 10-K/A, Annual Report | 1 | SEC Filings | ||
| 14.03. | Eterna Therapeutics Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 20.02. | Eterna Therapeutics adds biotech veteran Peter Cicala to board | 1 | Investing.com | ||
| 20.02. | Eterna Therapeutics Announces the Appointment of Peter Cicala, JD, to its Board of Directors | 2 | GlobeNewswire (USA) | ||
| 16.02. | Eterna Therapeutics Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 19.01. | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.01. | Eterna Therapeutics Inc. - S-8, Securities to be offered to employees in employee benefit plans | 1 | SEC Filings | ||
| 12.01. | Eterna Therapeutics files to sell 18.2M shares for holders | 1 | Seeking Alpha | ||
| 03.01. | Eterna Therapeutics Grants New President and CEO Sanjeev Luther Inducement Award Under Nasdaq Listing Rule 5635 (c)(4) | 1 | GlobeNewswire (USA) | ||
| 20.12.23 | Eterna Therapeutics names Sanjeev Luther as CEO | 1 | Seeking Alpha | ||
| 20.12.23 | Eterna Therapeutics Names Sanjeev Luther as President and Chief Executive Officer | 176 | GlobeNewswire (Europe) | CAMBRIDGE, Mass., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) ("Eterna" or the "Company"), a life science company committed to realizing the potential of mRNA cell engineering... ► Artikel lesen | |
| 15.12.23 | Eterna Therapeutics launches convertible debt and warrant financing of up to $9.2M | 1 | Seeking Alpha | ||
| 15.12.23 | Eterna Therapeutics Announces $9.2 Million Convertible Debt and Warrant Financing | 1 | GlobeNewswire (USA) | ||
| 14.12.23 | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 16.11.23 | Eterna Therapeutics Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.11.23 | Eterna Therapeutics Inc. - 10-Q, Quarterly Report | - | SEC Filings |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EPIGENOMICS | 1,575 | -3,37 % | EQS-News: Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024 | EQS-News: Epigenomics AG
/ Schlagwort(e): Personalie
Epigenomics AG: Ausscheiden des Vorstands Jens Ravens zum 30. April 2024
30.04.2024 / 15:00 CET/CEST
Für den Inhalt... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 1,030 | +3,00 % | Ist es schon so weit? Raus aus KI, Biotech kaufen: Nvidia, Evotec, Defence Therapeutics und Bayer im Fokus | Wieder ein Schlag ins Kontor! Zum Monatsschluss April stürzt die Technologiebörse Nasdaq zum dritten Mal ab und zeigt mit 17.333 Punkten erneut große Schwäche. Nach einem langen Aufwärtstrend des NDX... ► Artikel lesen | |
| GINKGO BIOWORKS | 0,987 | +4,31 % | Ginkgo Bioworks: Buy, Sell, or Hold? | ||
| BEAM THERAPEUTICS | 23,520 | +1,69 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 9,000 | +1,81 % | (RXRX) - Analyzing Recursion Pharmaceuticals' Short Interest | ||
| ONCOLYTICS BIOTECH | 1,090 | 0,00 % | Oncolytics Biotech to Host Conference Call to Discuss First Quarter Financial Results and Recent Operational Highlights | ||
| ASSERTIO | 0,998 | -2,68 % | Assertio Holdings Q1 2024 Earnings Preview | ||
| ARCTURUS THERAPEUTICS | 27,810 | +1,98 % | Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress | SAN DIEGO--(BUSINESS WIRE)--Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a global messenger RNA medicines company focused on the development of infectious disease... ► Artikel lesen | |
| SIGA TECHNOLOGIES | 10,680 | +5,22 % | SIGA Technologies Inc.: SIGA Technologies to Host Business Update Call on May 7 Following Release of First-Quarter 2024 Financial Results | ||
| MERRIMACK PHARMACEUTICALS | 15,010 | +0,07 % | Merrimack Pharmaceuticals announces notification of plan to delist common stock on Nasdaq | ||
| VIR BIOTECHNOLOGY | 10,420 | +0,29 % | Vir Biotechnology Provides Corporate Update and Reports First Quarter 2024 Financial Results | SAN FRANCISCO--(BUSINESS WIRE)--Vir Biotechnology, Inc. (Nasdaq: VIR) today provided a corporate update and reported financial results for the first quarter ended March 31, 2024.
"We are excited... ► Artikel lesen | |
| VERVE THERAPEUTICS | 6,470 | +0,94 % | Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | BOSTON, May 03, 2024 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage biotechnology company pioneering a new approach to the care of cardiovascular disease with single-course gene editing... ► Artikel lesen | |
| ARS PHARMACEUTICALS | 9,670 | -0,82 % | ARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Submits Response for neffy (epinephrine nasal spray) Marketing Authorization Application to EMA's CHMP and Enters License Agreement with CSL Seqirus for Commercialization of neffy in Australia and New Zealand | CHMP opinion on neffy Marketing Authorization Application anticipated in the second quarter of 2024 Response addresses all issues previously identified by CHMP, and includes results from a repeat... ► Artikel lesen | |
| BIO-PATH | 2,810 | +7,66 % | Looking Into Bio-Path Holdings' Recent Short Interest | ||
| BIOMEA FUSION | 12,510 | +1,46 % | Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., May 01, 2024 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (Nasdaq: BMEA) ("Biomea" or the "Company"), a clinical stage biopharmaceutical company focused on the discovery and development... ► Artikel lesen |
Das Unternehmen ETERNA THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von +0,050 (+2,78 %) liegt der Kurs bei 1,850 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
